\
&
Contact us
\
&
Contact us
Published on | 2 years ago
Programmes Digital, Industry & SpaceThere is 1 attachment connected to this article.
Attachments are only accessible for people with an account on the NCP Flanders website.
The Commission presents the results of 2022–2023 space-related research calls for proposals under Horizon Europe.
In total, €166 million will support 54 space research projects implemented by the European Health and Digital Executive Agency (HaDEA) and the EU Space Programme Agency (EUSPA).
The selected projects will bring breakthrough innovations and contribute to strengthening both the European Union Space programme and other space research priorities in various domains, from Earth observation to European Global Navigation Satellite System (EGNSS), secure telecommunications and autonomous access to space.
The selection will also boost the Union’s competitiveness and technological non-dependence and lead to the development of new services and downstream applications for Copernicus, Galileo, European Geostationary Navigation Overlay Service (EGNOS), and European Union Governmental Satellite Communications programme (GOVSATCOM).
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
